Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02411526 · ClinicalTrials.gov registry record · Phase 1
Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia
A Phase 1 study, sponsored by Zogenix.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02411526 is a Phase 1 study that has completed, run by Zogenix. The registered enrollment target is 60 participants.
The verdict
NCT02411526, a Phase 1 study, has completed, sponsored by Zogenix.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is an open-label, multiple dose, PK and safety study in patients with chronic, stable schizophrenia or schizoaffective disorder.
Interventions
- DRUG Oral Risperidone
- DRUG Risperdal Consta
- DRUG ZX003 (Risperidone-SABER®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-02 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02411526
The ClinicalTrials.gov registry entry for NCT02411526 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zogenix, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Oral Risperidone is the first listed.
NCT02411526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02411526 about?
NCT02411526 is a clinical study titled "Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia". This is an open-label, multiple dose, PK and safety study in patients with chronic, stable schizophrenia or schizoaffective disorder.
What is the current status of trial NCT02411526?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2015-02. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02411526?
The interventions under investigation include: Oral Risperidone (DRUG), Risperdal Consta (DRUG), ZX003 (Risperidone-SABER®) (DRUG).
Who is sponsoring clinical trial NCT02411526?
This trial is sponsored by Zogenix, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.